Drug Trial Radar · NCT06855264
A Cardiac Liability Study of Varegacestat in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Feb 24, 2025
Primary completion
Apr 8, 2025
Study completion May 6, 2025
Sponsor
- Lead sponsor
- Immunome, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical study is designed to study the effect of a single dose of varegacestat on cardiac repolarization in healthy adult participants.
Conditions
- Healthy Volunteer
Interventions
varegacestatDrug
Single oral dose of varegacestat
PlaceboDrug
Single oral dose of placebo
Moxifloxacin 400 mgDrug
Single oral dose of moxifloxacin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Placebo-corrected change from baseline QTc and varegacestat and its metabolite, AL102 MTB, plasma concentrationsTime frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.